We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
03 July 2019
On 3 May 2019 Health Canada released the new Guidance Document: Regulatory Requirements for Drug Identification Numbers. The guidance document provides "assistance on the interpretation of the regulatory requirements associated with a [drug identification number]", as well as "guidance to manufacturers on their obligation to accurately report to Health Canada [certain] notifications for a change of drug status". This particular guidance document replaces a number of Health Canada documents, including the following:
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.